advancing innovation to save lives

GHTC welcomes launch of first-ever WHO list of essential diagnostic tests

GHTC welcomes the publication today by the World Health Organization (WHO) of its first Essential Diagnostics List, a critical new tool to help guide governments on the vital diagnostic tests that should be made available through health care systems.
Learn More

Return On Innovation: Learn how global health R&D delivers for your state

Global health R&D matters globally and benefits you locally. Find out how US investments in global health R&D are paying economic and health dividends in your state.
View

Member Spotlight: HarvestPlus

HarvestPlus leads a global effort to improve vitamin and mineral nutrition and public health by developing and deploying staple food crops that are rich in vitamins and minerals.
Learn More

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 25 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn more
PATH/Katrina Peach
GHTC statement on TB high-level meeting delivered at WHA

A statement by GHTC and partners calling for the United Nations High-Level Meeting on Ending TB to issue a political declaration focused on increasing investments in tuberculosis (TB) R&D was delivered at the 71st World Health Assembly (WHA). The statement, which was prepared in partnership with Global Health Council, Infectious Diseases Society of America, Elizabeth Glaser Pediatric AIDS Foundation, and Partners in Health, also encourages the inclusion of child-specific targets for TB R&D and additional resources for R&D to combat drug-resistant TB.

PDF
PATH/Eric Becker
GHTC statement on access to medicines delivered at WHA

A statement by GHTC and partners calling for the World Health Organization to support a comprehensive approach to addressing barriers to access to medicines was delivered at the 71st World Health Assembly (WHA). The statement, which was prepared in partnership with Global Health Council, American Academy of Pediatrics, NCD Child, and the International Federation of Psoriasis Associations, notes the importance of strengthening regulatory systems and harmonizing processes.

PDF
View All News & Events

Community Event

PATH/Gabe Bienczycki
Empathy: The Emperor’s New Clothes –– or Public Health’s Emerging Superhero?
Matchboxology, USAID Center for Accelerating Innovation and Impact
Learn More

Member Event

RESULTS International Conference
RESULTS
Learn More
View All Events
WHO/L. Cipriani
WHA Roundup: Incremental steps forward on access and TB takes the limelight

What global health research advocates need to know about the 71st World Health Assembly (WHA).

Read More
Pan American Health Organization
What to watch at WHA 71

The 71st session of the World Health Assembly will see a number of debates that could impact global health R&D. Here is is what you need to know.

Read More
View Breakthroughs Blog

Our members work to improve health worldwide